(Q45236130)

11 December 2017

title

Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia (English)

1 reference

11 December 2017

0 references

B Bandelow

8

0 references

Steffen Moritz

object named as

S Moritz

10

0 references

author name string

D Naber

1

1 reference

11 December 2017

M Riedel

2

1 reference

11 December 2017

A Klimke

3

1 reference

11 December 2017

E-U Vorbach

4

1 reference

11 December 2017

M Lambert

5

1 reference

11 December 2017

K-U Kühn

6

1 reference

11 December 2017

S Bender

7

1 reference

11 December 2017

W Lemmer

9

1 reference

11 December 2017

R W Dittmann

11

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Acta Psychiatrica Scandinavica

11 December 2017

published in

1 reference

11 December 2017

volume

111

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

106-115

1 reference

Subject and observer-rated quality of life in schizophrenia.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

Clinical correlates of early medication adherence: West London first episode schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00486.X

10.1111/J.1600-0447.2004.00486.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference